ranged from 18 to 80 years (mean 52.9 years) and there was a male predominance (85% male). Nonfunctioning pituitary adenoma was the most frequent type (75.9%), followed by medication-resistant prolactinomas (22.2%) and 1 case of GH-secreting pituitary adenoma (1.9%). Among the 13 patients with functional giant pituitary adenomas, 12 were receiving medical treatment but had shown resistance to pharmaceutical agents, and 3 presented with apoplexy and acute neurological symptoms. In total, 16 patients (13 with nonfunctioning pituitary adenoma and 3 with prolactinoma) had undergone previous surgery, either microscopic transsphenoidal surgery or craniotomy; among them, 3 had multiple surgeries and 1 had received additional radiation therapy for a resistant prolactinoma. Only 29 patients (53.7%) had never been treated medically or surgically.
Clinical Presentation
The dominant clinical symptom at presentation was visual impairment affecting visual acuity, the visual field, or both, and occurred in 45 patients (83.3%; Table 1 ). Partial or complete pituitary insufficiency was evident in 28 patients (51.8%), including hypoadrenalism in 17 (31.5%), hypothyroidism in 20 (37%), hypogonadism in 17 males (35.4%), and GH deficits in 3 (GH levels were not available preoperatively in every patient). Two patients suffered from diabetes insipidus at presentation (1 after previous transsphenoidal surgery), while 7 patients (13%) presented with apoplexy. Seven patients (2 presenting with apoplexy and 5 without) suffered from cranial nerve palsies. One patient with a GH-secreting pituitary adenoma had clinical signs and symptoms of acromegaly.
Tumor Characteristics
Retrospective analysis of MRI studies showed variable tumor shape, pattern of extension, and contrast enhancement. Tumor volume was approximated by a modified ellipsoid volume ([A*B*C]/2), where A, B, and C were the maximum diameters of the adenoma in each of the 3 dimensions. The average tumor volume was 32 ). Giant pituitary adenomas were rounded in shape in 15 cases (27.8%), dumbbellshaped in 6 (11.1%), and multilobular in 33 (61.1%; Table  2 ). Regarding tumor location, 53 tumors (98.1%) occupied the sella, 50 (92.6%) extended to the suprasellar region, and 50 (92.6%) extended to the sphenoid sinus. Cavernous sinus invasion was evaluated according to the Knosp criteria 22 and was confirmed by intraoperative observation in every case; cavernous sinus invasion was present in 51 cases (94.4%; unilaterally in 21 cases and bilaterally in 30). Among these 51 cases with cavernous sinus invasion, 14 (27.5%) showed radiographic invasion of the lateral wall of the cavernous sinus with tumor extension toward the ipsilateral middle fossa. Using the Knosp criteria, among the total of 108 cavernous sinuses, 12 were classified as Grade 0 (11.1%), 6 were Grade 1 (5.6%), 24 were Grade 2 (22.2%), 35 were Grade 3 (32.4%), and 31 were Grade 4 (28.7%). Grade 4 tumors represent the cases with radiographic evidence of invasion of the lateral wall of the cavernous sinus. The upper clivus was involved in all cases with erosion of the posterior clinoids. Further intracranial tumor extension was assessed in the sagittal plane (anterior fossa), coronal plane (middle fossa), axial plane (posterior fossa), and ventricular system. In 13 cases (24%) the tumor extended to the frontal lobe; in 14 cases (25.9%), the tumor that invaded the cavernous sinus eroded the lateral wall of the sinus and extended to the temporal lobe (Fig. 1 ); 14 patients (25.9%) had retroclival extension (Fig. 2) ; and in 23 cases (42.6%) the adenoma extended to the third (Fig. 2) or lateral ventricle. Intraventricular tumor extension was confirmed intraoperatively in every case. The tumor showed homogeneous enhancement after contrast administration in 28 patients (51.9%) and heterogeneous enhancement in 26 (48.1%; Table 2 ).
Surgical Management and Adjuvant Therapies
All of the patients underwent EES. The goal of surgery was optic apparatus (nerves/chiasm/tract) decompression and the maximum possible safe tumor resection. Gross-total resection was not possible in the majority of cases given the size, shape, and extension of the tumor. In 5 patients, we planned a staged approach. Based on the location and extension of the giant adenoma, we planned an endoscopic endonasal approach to facilitate the most rad ical tumor removal by simultaneously combining trans sel lar, transtuberculum, transplanum, transcavernous, transpterygoid, and transclival approaches ( Table 3) .
As part of the initial management, 11 patients (20.4%) received adjuvant radiation therapy for residual tumor, including radiosurgery in 8 cases. Three more patients underwent radiosurgery in a later stage for tumor recurrence. Ten patients with functional pituitary adenomas (9 prolactinomas and 1 GH-secreting pituitary adenoma) continued to receive medical treatment after surgery.
Evaluation of Surgical Results
Clinical outcome after EES was assessed using postoperative visual tests (visual acuity and visual fields), endocrinological studies, and clinical examinations. We evaluated the degree of tumor resection on postoperative MRI. In most cases, immediate postoperative MRI was performed within a few days after surgery and used as a baseline for further imaging follow-up. The degree of resection was confirmed with 3-month postoperative MRI in all but 3 patients, who were all lost to followup. The volume of residual adenomas was calculated with the same mathematical formula ([A*B*C]/2) that was used for the initial tumor measurement. Cases involving postoperative linear contrast enhancement, in which tumor volume could not in fact be measured, were not considered GTR. Additionally, the absence of tumor on postoperative MRI had to be accompanied by evidence of biochemical remission in cases of functional adenomas. Based on these criteria, we conducted a multivariable analysis of the degree of tumor resection. In residual tumors, we considered the degree of resection near total when more than 90% of the tumor was resected and partial for less than 90% resections.
Some patients with pituitary dysfunction do not require hormone replacement therapy. In an attempt to maintain strict criteria regarding postoperative endocrinological deficit, we determined postoperative pituitary dysfunction by biochemical examinations and not only by the need for treatment.
Although optic apparatus decompression rather than GTR is the goal of surgery in most giant pituitary adenomas, we evaluated the GTR rates of these irregularly extending, invasive giant tumors in an attempt to understand the advantages and limitations of EES. The tumor size (< 50 mm, 50-60 mm, > 60 mm), shape (rounded, dumbbell, multilobular), extension (anterior, middle, posterior fossa, ventricular system), evidence of apoplexy, and previous treatment (medical or surgical) were studied as independent factors to evaluate their influence on the degree of tumor resection when EES is applied.
Statistical Analysis
Patient demographics, clinical presentation, tumor characteristics, surgical approaches, and outcomes were analyzed using descriptive statistics. Gross-total resection rates for every studied tumor characteristic were compared using the chi-square and Fisher exact tests within the studied variable. A p value < 0.05 was considered statistically significant. Data were collected using Microsoft Excel 2010 (Microsoft Corporation).
Results

Clinical Outcome
Improvement or normalization of vision was achieved in 36 patients (80%; Table 4 ). Two patients (3.7%) experienced visual deterioration due to apoplexy of residual tumor; 1 of them showed partial recovery after reoperation for evacuation of the hematoma, and the other had a prolonged stay in the intensive care unit without available visual follow-up. In 1 patient who presented with visual impairment, postoperative visual examination was not available. Twenty-two (78.6%) of 28 patients with preexisting pituitary dysfunction remained unchanged after EES. Only 1 patient recovered from pituitary impairment; he presented with secondary adrenal insufficiency requiring replacement with hydrocortisone and he was fully recovered after EES. Five other patients (17.8%) experienced further deficiency in 1 or more hypothalamopituitary axes (adrenal insufficiency in every case combined with thyroid dysfunction in 3 patients). Preexisting cranial nerve palsy persisted after surgery in 2 patients (28.6%) and improved or normalized in every other case, while headache and altered mental status resolved in the majority of cases.
Degree of Tumor Resection
Eleven patients (20.4%) underwent GTR ( Fig. 1) after the initial treatment with EES. Although GTR was not possible in the majority of the cases, near-total (> 90%) resection was achieved in 36 patients (66.7%), resulting in a high rate of post-EES visual improvement (80%), which was the main goal of surgery. Primary giant pituitary adenomas had a better surgical outcome compared with previously resected tumors (Table 5 ), but this did not reach statistical significance (p = 0.144; discussed below). The more complicated the tumor configuration, the lower the radical resection rate. More than 90% of rounded giant pituitary adenomas were resected in 93% of the cases, with GTR attained in 46.7% (Fig. 1 ). On the other hand, GTR for irregular tumor configuration occurred in only 6.1% (Fig. 2) . Although the resection rates depend on multivariate parameters, extreme intracranial tumor extension was also associated with lower rates of GTR.
To better understand the advantages and limitations of EES in giant pituitary adenoma resection, we analyzed the rate of GTR according to tumor size, shape, extension, evidence of apoplexy, and previous treatment (Table 6 ). Tumor size, extension to the ventricular system, extension to the anterior or posterior fossa, apoplexy, and previous treatment (surgical or medical) were not limitations of GTR with EES. Primary tumors had a better surgical outcome compared with previously treated adenomas, but there was not a significant difference. On the other hand, tumor shape, and particularly a multilobular tumor configuration, was the most important factor that limited the degree of tumor resection. The extension of the adenoma in the coronal plane (cavernous sinus or even more lateral to the temporal lobe) was a clear limitation of EES. Comparing the degree of GTR between tumors that eroded only the medial wall of the cavernous sinus (n = 37) and those that eroded the lateral wall of the cavernous sinus and extended to the temporal lobe (n = 14), we found that cavernous sinus invasion in general is not a limitation for GTR with EES; however, tumor extension lateral to the intracavernous segment of the carotid artery with expansion or erosion of the lateral wall of the cavernous sinus represents the real limitation of the endoscopic endonasal approach. In terms of relating these findings to the welldescribed Knosp criteria, complete resection of the tumor from the cavernous sinus was not possible in any of the Knosp Grade 4 cases; however, complete evacuation of the cavernous sinus was achieved in 27 (77.1%) of 35 cavernous sinuses with Grade 3 invasion and in 40 (95.2%) of 42 with Grade 0-2 invasion. 
Complications and Management
The most common surgical complication was postoperative CSF leak, which occurred in 9 patients (16.7%; Table 7 ). It should be noted that this rate has been reduced to 7.4% in recent years with routine use of a vascularized nasoseptal flap for reconstruction. Specifically, after 2006 we had 2 cases of CSF leak among 27 EESs for giant pituitary adenomas, while in the earlier years the rate of CSF leak was 25.9% (7 cases among 27 EESs). These CSF leaks were managed with reoperation (EES) alone (n = 3), lumbar drain placement alone (n = 2), or a combination of EES and lumbar drain placement (n = 4), based on the surgeon's judgment and perceived severity and source of the leak. Among these patients, 2 developed meningitis that was treated with antibiotics without any further clinical consequence. A third case of postoperative meningitis occurred in a patient without postoperative CSF leak but with a complicated postoperative course requiring multiple surgeries.
Six transient cranial nerve palsies occurred: 2 cases of left third cranial nerve palsy after postoperative apoplexy of residual tumor and 4 cases of left fourth cranial nerve palsy in cases with tumor extension in the cavernous sinus. All of the iatrogenic cranial nerve palsies re- * All values given as number of cases (%). solved within days or weeks. Interestingly, all of the cranial nerve palsies were on the patients' left sides. Postoperative diabetes insipidus was observed in 13 cases, resulting in permanent diabetes insipidus in only 5 (9.6%). Two patients (3.7%) developed syndrome of inappropriate antidiuretic hormone that resolved with water restriction.
At presentation, 26 patients were endocrinologically intact; among them, 4 had evidence of new pituitary deficit postoperatively (15.4%). Among 28 patients who presented with some degree of pituitary dysfunction, 5 (17.9%) had additional pituitary deficit postoperatively. In total, 9 patients had a new pituitary deficit following EES. All 9 patients developed adrenal insufficiency (24.3% among 37 patients without a preoperative adrenal deficit). Seven patients experienced new thyroid dysfunction (20.6% among 34 with preoperative intact thyroid function). Three male patients showed low testosterone levels after EES (9.7% among 31 males with normal preoperative testosterone levels) and 2 of them required treatment. Two patients demonstrated a GH deficit not requiring treatment (preoperative GH levels were not available in every patient). Two patients with postoperative apoplexy of residual adenoma underwent reoperation for hematoma evacuation. Two patients suffered from postoperative respiratory failure requiring tracheostomy on 1 occasion. Pulmonary embolism occurred in 3 cases and was treated with warfarin. One patient developed immediate postoperative transient hemiparesis (transient ischemic attack) that eventually resolved.
During a mean follow-up period of 37.9 months, 6 patients in this cohort died. No deaths occurred in the immediate postoperative period (within 1 month after EES). Three patients (5.5%) died within 1 year after surgery as a result of associated complications (hemorrhagic complications of anticoagulation therapy for pulmonary embolus [n = 1], multiple organ failure [n = 1], and respiratory failure and meningitis [n = 1]). One additional patient died due to disease progression 10 months after surgery, and in 2 cases, death was the result of other medical problems and happened 28 and 84 months after EES.
Recurrences and Follow-Up
During the mean follow-up period of 37.9 months (range 1-114 months), 8 patients (14.8%) showed tumor regrowth and were managed with radiosurgery (n = 1), repeat EES alone (n = 4), or a combination of EES and radiosurgery (n = 3). In total, 54 patients underwent 66 surgical procedures (EES) and 14 received radiation therapy as part of the initial management or recurrence treatment.
All the patients who underwent GTR (20.4%) remained free of tumors. Of those with residual tumor, including those with recurrences who were further treated, 32 (59.3%) had a stable tumor, 7 (13%) showed decreased residual volume, and 4 (7.4%) had a recent asymptomatic increase of residual volume and are being closely monitored during follow-up (Table 8) . Although primary giant adenomas had a higher rate of GTR, and thus remain free of tumor, a high percentage of recurrent giant adenomas had stable residual tumor.
Discussion
Giant pituitary adenomas can be extremely challenging to manage using surgery alone. The use of medical therapy when indicated, and possibly radiation therapy, is usually crucial for achieving long-term tumor control. Surgery, however, remains the first step in the treatment of most of these tumors. Recently the use of endoscopes has been adopted by many pituitary surgeons. Endoscopic endonasal surgery allows more panoramic visualization and wider access to the skull base compared with the tunnel vision and speculum limitations of the microscopic transsphenoidal approach. 3, 8, 19, 20 Technological advances such as angled endoscopes, specialized instrumentation, image guidance, and neurophysiological monitoring of the brain and cranial nerves are routinely used and have extended the indications of EES. To our knowledge, this report of 54 cases is the largest series of giant pituitary adenomas treated endoscopically.
Goals of Surgery
The main goals of surgery for giant pituitary adenomas are visual improvement, recovery from endocrinological and neurological symptoms, and maximal tumor resection. Unfortunately, the inclusion criteria in published series regarding tumor size and extension are usually not specified in detail, and given their variety, the surgical outcomes are very heterogeneous and not easily available for comparison. Table 9 summarizes the outcome of the most detailed surgical series.
Although postoperative visual improvement varies among published series, it is more likely after transsphenoidal than transcranial surgery, with rates of approximately 80%. 2, 12, 27 In a more recent series that includes microscopic transsphenoidal approaches (occasionally endoscopic-assisted), the postoperative visual improvement rate reached 81.5%. 7 In our series, visual improvement occurred in 36 (80%) of 45 patients with preoperative visual defect; among these patients, 9 (20%) experienced complete visual recovery postoperatively. Based on this expe- rience, the EES is at least as effective as transsphenoidal surgery regarding visual improvement. Postoperative improvement of hypopituitarism after surgery for giant pituitary adenomas has not been studied in detail. The reported hormonal improvement rates of 35%-50% after transsphenoidal surgery are in reference to macroadenomas and cannot be applied to giant pituitary adenomas, in which hypopituitarism is usually long-standing and more difficult to be corrected after surgery.
14,28,29 de Paiva Neto et al. 7 reported that 22.5% of giant pituitary adenomas treated with the microscopicor endoscopic-assisted transsphenoidal approach showed resolution of at least 1 anterior pituitary hormone deficiency. In our experience, only 1 patient with preexisting hypoadrenalism (3.6%) recovered after EES, while in 22 (78.6%) the pituitary function remained unchanged after surgery. Given that some patients with giant adenomas had undergone previous surgeries or even radiation therapy and most of them presented for urgent treatment, hormonal data are often incomplete for full evaluation.
Although there are no reported results in previous studies regarding the improvement of ophthalmoplegia after surgery for giant pituitary adenomas, our technique was very successful, achieving 71.4% improvement of preexisting cranial nerve palsies. Among 7 patients with cranial nerve palsies, 2 (28.6%) showed complete recovery after surgery. This may be a consequence of improved access and visualization of the lateral cavernous sinus and the use of intraoperative electromyographic monitoring of extraocular nerves.
It is generally accepted that complete removal is unlikely in giant pituitary adenomas. 2, 7, 27, 33 Once again, the data reported in the literature regarding the rates of GTR are variable. Mortini et al., 27 in a very detailed report of their experience, found a GTR rate of 14.7% using mostly microscopic transsphenoidal surgery. Other authors have reported GTR rates of 29.65% or 41%, but it is unclear if these patients were evaluated using the same criteria.
7,18
We consider a surgery to be GTR only when there is the absence of any hint of residual tumor on postoperative MRI and resolution of hypersecretory symptoms in cases of functional pituitary adenomas. Using these criteria, the overall GTR with EES was 20.4%. However, this rate was significantly different for different tumor configurations (p = 0.002); for rounded adenomas the GTR rate was 46.7%, for dumbbell-shaped the rate was 33.3%, and the rate was only 6.1% for multilobular tumors (Fig. 3) . Gross-total resection of giant pituitary adenomas was dependent on multiple factors, and the overall low resection rates confirm the difficulty in their management.
Surgical Approaches and Limitations
Transcranial and Microscopic Transsphenoidal Surgery. The transsphenoidal approach involves fewer complications than transcranial procedures and represents the first choice in the surgical treatment of giant adenomas. 7, 11, 27 Cavernous sinus invasion is one of the main limitations that precludes complete tumor resection. 7, 10, 13, 18, 27 Age, type of adenoma, maximum tumor diameter, degree of suprasellar extension, retrosellar expansion, ethmoidal and nasal involvement, history of previous pituitary surgery, and type of surgery do not affect surgical outcome with the transsphenoidal approach. 27 However, dumbbellshaped tumors or irregular adenomas and tumor extension into the subfrontal region, retrochiasmatic area, temporal region, or posterior fossa are considered contraindications for transsphenoidal surgery, and most authors suggest a transcranial approach for these cases.
2,27,32,33 Thus, the transcranial route is usually adopted as a second choice if the transsphenoidal approach is not indicated or has failed to achieve the desired results, or when a residual suprasellar adenoma does not descend and is considered fibrotic following transsphenoidal surgery. scopic transsphenoidal approaches, resulting in a GTR rate as low as 9.6%, 7,18,27 this was not a significant limitation with EES. In our experience, with wider exposures and angled endoscopes, invasion of the medial wall of the cavernous sinus does not restrict tumor resection. This is exemplified by compete evacuation of the cavernous sinus in 27 (77.1%) of 35 cavernous sinuses with Knosp Grade 3 invasion and in 40 (95.2%) of 42 with Grade 0-2 invasion. The limitation of EES is invasion of the lateral wall of the cavernous sinus and extension of the tumor to the temporal lobe. In fact, it is not the extreme lateralization of the tumor that prohibits resection, but the natural boundary of the cranial nerves at the lateral wall of the cavernous sinus. As a result of a dogmatic respect for this boundary, no cases of Knosp Grade 4 invasion underwent complete removal. In such a case, any midline approach is inadequate to achieve GTR and this part of the tumor can only be approached with an open craniotomy. It is rare that this lateral component is significant or symptomatic enough to warrant resection, even in the setting of postoperative apoplexy. This is illustrated in this series where no adjuvant transcranial approaches were used or found to be necessary for long-term tumor control.
Endoscopic Endonasal Surgery. Although cavernous sinus invasion is the main limitation of open and micro-
Multilobular giant adenomas, especially when they extended far into the anterior fossa, were the most significant limitation of EES (p = 0.002). In lobular tumors there is no wide communication between the intra-and suprasellar tumor components (Fig. 4) , and the residual adenoma of the frontal lobe is unlikely to descend into a more accessible region. In this case, GTR can be achieved with a combined endonasal/transcranial approach or possibly with a staged endoscopic endonasal approach after several months.
1
Retrochiasmatic extension of the tumor and expansion into the ventricular system is considered a contraindication for microscopic transsphenoidal surgery.
2,33
However, intraventricular tumor extension does not prohibit complete resection with EES. The panoramic visualization and wide exposure provided by the endoscopic endonasal approach enables safe tumor resection from the retrochiasmatic area through the natural corridor created by the tumor (Fig. 5) . The endonasal route is the only one that provides a direct access into the long axis of the tumor.
Tumor extension to the posterior fossa could be an indication for an open approach.
1 With the transclival endoscopic endonasal approach, this part of the adenoma can easily be accessed and removed (Fig. 6 ). Intraoperative image guidance and neurophysiological monitoring of the brainstem and abducens nerve facilitate accurate tumor localization and prevent neurological damage.
Other variables, such as tumor apoplexy at presentation, can be consistently favorable in pituitary surgery. In the present series, apoplexy was associated with a favorable surgical outcome without, however, being a significant factor for GTR. This finding has been reported, and it is considered that extensive necrotic and hemorrhagic changes of the pituitary adenoma may facilitate complete removal. 24 In addition, the tumor may have been largely or completely infarcted, leading to good long-term radiographic outcomes. Finally, previous treatment may influence the degree of tumor resection in giant adenomas to a small degree, as previously noted.
27
Surgical Complications
In general, giant pituitary adenomas have a higher surgical complication rate, highlighting the difficulty of their treatment. The most common complication of EES was postoperative CSF leak (16.7%) necessitating reoperation and/or lumbar drain placement. This complication rate was even higher (25.9%) during the early years of our experience. After routine adoption of the vascular- ized nasoseptal flap for reconstruction, the CSF leak rate was reduced to 7.4%. 21, 34 However, this rate is still high compared with CSF leaks after routine transsphenoidal surgery, 7, 27 likely due to wider exposures and more extensive arachnoid dissection.
Worsening of pituitary function occurred in 16.7% of patients after EES, which is comparable to new endocrinopathy after microscopic transsphenoidal surgery and lower than new pituitary dysfunction after transcranial surgery. 2, 7, 27 Postoperative loss of pituitary function is generally more common in transcranial pituitary surgery.
2
Diabetes insipidus is also more common following transcranial than transsphenoidal surgery for giant adenomas. 2, 27 In transsphenoidal series, the reported incidence of permanent postoperative diabetes insipidus is 8.2% 27 and 10.4%. 7 With the endoscopic endonasal approach, permanent postoperative diabetes insipidus occurred in 9.6%, similar to the transsphenoidal experience.
Postoperative visual deterioration is also more common after transcranial than transsphenoidal surgery and can be as high as 22%. 11, 27 In our series, we counted 2 cases (3.7%) of transient postoperative visual deterioration that occurred after apoplexy of residual adenoma. Residual adenomas are more prone to hemorrhage with resultant clinical deterioration. As a result, intrasellar hemorrhage may occur during the early postoperative period after the removal of an adenoma, which is more common after partial resection of giant pituitary adenomas. 4, 17, 23 Postoperative cranial nerve dysfunction is a frequent complication after transcranial surgery for tumors involving the cavernous sinus, and it affects the oculomotor nerve most often.
9 Permanent ophthalmoplegia has not been reported in large transsphenoidal series of giant pituitary adenomas and did not occur in our patient series.
7,27 However, we had 6 cases (11%) of transient postoperative cranial nerve palsies that resolved after days or weeks; 2 developed after apoplexy of residual adenoma and 4 due to dissection of tumor from the cavernous sinus. Interestingly, all of the cranial nerve palsies were on the left side. Further studies are necessary to assess whether handedness of the surgeon is a potential limitation or risk factor during EES.
Other complications such as syndrome of inappropriate antidiuretic hormone, hydrocephalus, pulmonary embolus, or cerebral ischemia may occur after transcranial or transsphenoidal surgery (microscopic or endoscopic) and are not correlated directly with the surgical approach. Mortality rates after surgery are higher in giant pituitary adenomas compared with non-giant adenomas and range from 3.2% to 18.7%. 16, 25, 27, 31 One of the leading causes of postoperative death is apoplexy of the residual adenoma. 4 In our experience, there were no immediate postoperative deaths, but 3 patients (5.5%) died within 1 year after surgery due to multiple subsequent complications.
Conclusions
Multiple factors influence the surgical outcome of giant pituitary adenomas. The treatment of these tumors can be difficult to standardize and should be tailored to individuals. Although long-term disease control may necessitate the use of adjuvant treatments, the initial management of giant adenomas is maximum resection. Endoscopic endonasal surgery has been used in recent years and enables tumor resection from the cavernous sinuses, intraventricular system, and retroclival region. The true limitations of this approach are a multilobular configuration of the adenoma and extension beyond the lateral wall of the cavernous sinus. With the exception of increased CSF leak rates that continue to decline with the use of vascularized nasoseptal flap reconstruction, the complications of EES are equal to, if not less than, the reported surgical complications of other approaches for these extremely challenging tumors.
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